JAMA Cardiology
@JAMACardio
JAMA Cardiology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.
ID:3415715278
http://ja.ma/tjamacardiology 11-08-2015 16:46:50
13,4K Tweets
44,3K Followers
367 Following
Most viewed in the last 7 days from JAMA Cardiology:
What is the optimal antiplatelet regimen in patients with ACS undergoing PCI who are at both high bleeding and ischemic risks?
ja.ma/3UDJ0lW
Most viewed in the last 7 days from JAMA Cardiology:
What is the optimal antiplatelet regimen in patients with ACS undergoing PCI who are at both high bleeding and ischemic risks?
ja.ma/44k38wj
Most viewed in the last 7 days from JAMA Cardiology:
Does plozasiran, an investigational APOC3-targeted small interfering–RNA therapeutic, safely and effectively reduce serum triglyceride level in patients with severe hypertriglyceridemia?
ja.ma/3JpT3o6
Catheter ablation for AF was associated with reduced risk of HF events in patients with HFrEF but had limited or no benefit in HFpEF. ja.ma/44lr82o PHRI.ca Population Health Research Institute 🇨🇦
JAMA Medical News Director jenabbasi and Douglas Drachman discuss late-breaking research from #ACC24 and World Congress of Cardiology. Hosted on @amaedhub. ja.ma/3W4m6oE American College of Cardiology
Most viewed in the last 7 days from JAMA Cardiology:
Does plozasiran, an investigational APOC3-targeted small interfering–RNA therapeutic, safely and effectively reduce serum triglyceride level in patients with severe hypertriglyceridemia?
ja.ma/3W576XI
Most viewed in the last 7 days from JAMA Cardiology:
Is antibiotic prophylaxis associated with decreased risk of infective endocarditis after invasive dental procedures?
ja.ma/4aR5xR8